Quantcast

Latest Drug safety Stories

2014-05-19 08:29:19

Scilex has commenced with its pivotal bioequivalence study of Ztilido versus Lidoderm® in accordance with FDA recommendations to support approval of Ztilido submitted as a 505(b)(2) NDA MALVERN, Pa., May 19, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has initiated a pivotal pharmacokinetic (PK) study of its investigational...

2014-05-16 08:26:43

CUPERTINO, Calif., May 16, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the International Anesthetic Research Society (IARS) Annual Meeting. The meeting will be held on May 17-20 at the Fairmont Queen Elizabeth Hotel in Montreal. "Bupivacaine is a widely used local anesthetic...

2014-05-12 23:07:22

Important webinar to examine the first regulatory year of EU regulations regarding cosmetovigilance. The live broadcast takes place on Thursday, June 5, 2014 at 11:00am EDT (16:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) May 12, 2014 The first anniversary is approaching for European regulations for mandatory reporting of serious adverse events temporally related to cosmetic use. Reporting of these events is often complicated by a product’s status as drug in one region, but a cosmetic in...

2014-05-08 23:08:58

Introducing eCongress on Pharmacovigilance, a new webinar series taking place throughout May to June 5th. The online series, which is free to attend, will provide professionals and practitioners gain current insight on drug safety monitoring, regulatory affairs and safety issues with prominent leaders of the industry. Toronto, Canada (PRWEB) May 08, 2014 During the series, featured speakers will share their perspectives and insights on key topics such as information management and...

2014-05-07 08:33:35

CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the...

2014-05-06 12:26:53

Georgia Prevention Initiative Awareness Campaign ATLANTA, May 6, 2014 /PRNewswire-USNewswire/ -- According to the Centers for Disease Control and Prevention (CDC) in 2012, "Overdose deaths involving prescription opioid analgesics, which are medications used to treat pain, have increased to almost 17,000 deaths a year in the United States." That is the equivalent of a large jumbo jet full of people disappearing every week for one year! The Georgia Prescription Drug Abuse Prevention...

2014-05-01 23:07:07

The U.S. Pharmacopeial Convention (USP) has proposed new and revised standards for organic impurities in drug substances and drug products—one of the critical quality attributes that has the potential to affect drug safety and efficacy. Rockville, MD (PRWEB) May 01, 2014 The U.S. Pharmacopeial Convention (USP) has proposed new and revised standards for organic impurities in drug substances and drug products—one of the critical quality attributes that has the potential to affect drug...

2014-05-01 16:33:40

In the news release, New Market Impact Study on Prescription Requirement for Pseudoephedrine Underscores Call for Alternative Solutions, issued 01-May-2014 by Consumer Healthcare Products Association over PR Newswire, we are advised by the company that the content has been updated. The complete, corrected release follows: New Market Impact Study on Prescription Requirement for Pseudoephedrine Underscores Call for Alternative Solutions Avalere Health Determines Prescription Legislation Will...

2014-05-01 16:32:15

BRISBANE, Calif., May 1, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014. The company also highlighted recent clinical development and business highlights, and raised its forward-looking revenue guidance for 2014. http://photos.prnewswire.com/prnvar/20120827/SF62570LOGO InterMune reported Esbriet(®) (pirfenidone) revenue in the first quarter of 2014 of $30.3 million, compared with $10.5 million in the...

2014-05-01 16:31:18

Avalere Health Determines Prescription Legislation Will Significantly Increase Cost of Healthcare WASHINGTON, May 1, 2014 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) today highlighted a new market-impact study conducted by Avalere Health and supported by CHPA. The study examined the potential market impacts of a prescription-only policy for cold and allergy medicines containing pseudoephedrine (PSE) compared to the implementation of real-time, stop-sale technology to...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related